Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05752552
Other study ID # DO2.22.01
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date December 20, 2022
Est. completion date April 2025

Study information

Verified date March 2024
Source DeuterOncology
Contact Timothy Perera, PhD
Phone +32473558353
Email tperera@deuteroncology.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is a first-in-human, open-label, 2-part, Phase 1 dose escalation study of DO-2, administered orally to patients with advanced or refractory solid tumours, with MET aberrations, and no available, approved therapeutic alternative.


Description:

In Part 1, a Simon Design 3 accelerated titration design will be followed. One patient will be enrolled per cohort, until grade 2 toxicity is observed. Three sequential patients per cohort will be enrolled thereafter, with a minimum of 1 week between first dose administration in the first patient and the subsequent ones, in those latter cohorts.


Recruitment information / eligibility

Status Recruiting
Enrollment 25
Est. completion date April 2025
Est. primary completion date October 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - 18 years or older - histologically or cytologically confirmed advanced or refractory solid tumour and no longer eligible for approved, available standard therapies. Tumour types must have: 1. proven MET activating mutations, determined by previous next generation sequencing (NGS), whole exome sequencing (WES), whole transcriptome sequencing (WTS) or other genomic analysis methods, or 2. proven amplification (= 10 copies) on archived tumour tissue. or 3. Hereditary Renal Papillary Cancer - measurable disease in accordance with RECIST 1.1 - Eastern Cooperative Oncology Group (ECOG) performance status = 1 - adequate bone marrow function, without the support of cytokines - adequate liver function - adequate renal function - agree to follow the contraception requirements of the trial - signed informed consent, indicating study patients understand the purpose of and procedures required for the study and are willing to participate in the study. Exclusion Criteria: - major surgery within 3 weeks before enrollment - chemotherapy (in the case of nitrosoureas and mitomycin C within 6 weeks), radiotherapy, immunotherapy, or any other study drug within 3 weeks before study drug administration - antibody based cancer therapy within 4 weeks before administration of the first dose of DO-2 - patients who became progressive on previous treatment with a MET-kinase inhibitor - patients with brain metastases are excluded unless all of the following criteria are met: 1. CNS lesions are asymptomatic and previously treated 2. No ongoing requirement for corticosteroids as therapy for CNS metastases 3. Imaging demonstrates stability of disease > 28 days from last treatment for CNS metastases - leptomeningeal involvement (leptomeningeal carcinomatosis) - history of uncontrolled heart disease including unstable angina, congestive heart failure, myocardial infarction within preceding 12 months, clinically significant rhythm or conduction abnormality, congenital long QT syndrome, obligate use of a cardiac pacemaker, QTc at screening greater than 450 milliseconds in males and greater than 470 milliseconds in females - uncontrolled arterial hypertension despite appropriate therapy - positive pregnancy test (urinary beta-hCG) at screening (applicable to women of child-bearing potential who are sexually active) - mental status alteration or history of major psychiatric illness, which may potentially impair patient's compliance with study procedures - signs and symptoms of active infection requiring systemic therapy - other medical condition (e.g. pre-existing kidney dysfunction) that in the opinion of the investigator makes it undesirable for a patient to participate

Study Design


Intervention

Drug:
DO-2
Deuterated MET kinase inhibitor

Locations

Country Name City State
Belgium Institut Roi Albert II - UC Louvain Bruxelles
Belgium UZA Edegem
Belgium Universitair Ziekenhuis Gent Gent
France Centre Georges-François Leclerc - CHU Dijon Dijon
France Institut Cœur Poumon - CHU Lille Lille
France Centre Léon Bérard Lyon
Netherlands Radboud UMC Nijmegen
Netherlands Erasmus Medical Centre Rotterdam

Sponsors (1)

Lead Sponsor Collaborator
DeuterOncology

Countries where clinical trial is conducted

Belgium,  France,  Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of subjects who experience Dose Limiting Toxicities (DLTs) Only toxicities that occur during Cycle 1 will be considered for the purposes of defining DLT and for dose escalation, but toxicities that occur in all cycles will be recorded and considered in decisions about the Maximum Tolerated Dose. DLTs are defined as toxicities that meet pre-defined severity criteria. Toxicity grading will be performed in accordance with NCI-CTC Version 5.0. Baseline up to Week 4
Primary Number of subjects who experience specific treatment-related adverse events (TRAEs) Number of subjects with specific treatment-related adverse events for each dose group.
AE refers to any untoward medical occurrence or deterioration of existing medical event after the subject signed the ICF, whether or not considered related to the study treatment. TRAEs are any event that occurs after the subject has received study treatment. AE grading will be performed in accordance with NCI-CTC Version 5.0.
Baseline up to Week 36
Primary Determination of the Maximum Tolerated Dose (MTD) The MTD in milligram is defined as the highest dose at which less than one third of the subjects in a dose level cohort experience DLT. Baseline up to Week 4
Secondary Maximum observed concentration (Cmax) and Area under the curve (AUC) of DO-2 Determine the Cmax and AUC of DO-2 and its main metabolites in plasma sampled at different timepoints during Cycle 1. Baseline up to Day 23
Secondary Time over treshold (ToT) for DO-2 Time by which the observed concentration of DO-2 in plasma is above the expected efficacy treshold. Baseline up to Day 23
Secondary Objective responses seen in Part I and objective response rate (ORR) in Part II ORR is defined as the proportion of subjects with confirmed CR or confirmed PR. Radiologic assessment will be repeated after every second cycle (or more frequently if clinically indicated) and using same methodology as at baseline. Response assessment (radiologic) will be determined in accordance with RECIST (version 1.1) and current disease specific solid tumour response criteria. Baseline through study completion, an average of 36 weeks
Secondary Duration of response (DoR) DoR is defined as the duration from the first documentation of objective response to the first documented disease progression (based on RECIST Version 1.1) or death due to any cause, whichever occurs first. Baseline through study completion, an average of 36 weeks
Secondary Progression-free survival (PFS) PFS is defined as the time from the start of treatment until the first documentation of disease progression or death due to any cause, whichever occurs first (based on RECIST Version 1.1). Baseline through study completion, an average of 36 weeks
Secondary Overall survival (OS) OS defined as the time from the first dose to death from any cause. Baseline through study completion, an average of 36 weeks
See also
  Status Clinical Trial Phase
Completed NCT03918538 - A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors N/A
Recruiting NCT05078918 - Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors N/A
Active, not recruiting NCT04548830 - Safety of Lung Cryobiopsy in People With Cancer Phase 2
Completed NCT04633850 - Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT05583916 - Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery N/A
Completed NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Not yet recruiting NCT06376253 - A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers Phase 1
Recruiting NCT05898594 - Lung Cancer Screening in High-risk Black Women N/A
Active, not recruiting NCT05060432 - Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Active, not recruiting NCT03575793 - A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer Phase 1/Phase 2
Terminated NCT01624090 - Mithramycin for Lung, Esophagus, and Other Chest Cancers Phase 2
Terminated NCT03275688 - NanoSpectrometer Biomarker Discovery and Confirmation Study
Not yet recruiting NCT04931420 - Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels Phase 2
Recruiting NCT06052449 - Assessing Social Determinants of Health to Increase Cancer Screening N/A
Recruiting NCT06010862 - Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors Phase 1
Not yet recruiting NCT06017271 - Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
Recruiting NCT05787522 - Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk

External Links